Neuroscience

Explore the role of primary antibodies targeting CD proteins in neurobiology and cancer research. Read more to discover how these antibodies facilitate precise cell population identification in the nervous system and contribute to human cancer disease diagnosis and prognosis.

Explore the importance of new biomarkers in glioma research and their potential to revolutionize diagnosis, prognosis, and treatment of this aggressive brain tumor. Discover new emerging biomarkers that will help to enhance patient outcomes and guide personalized therapeutic strategies.

The British Neuroscience Association (BNA) hosted its 6th International Festival of Neuroscience in April. Atlas Antibodies was there promoting his catalog of primary antibodies for Neuroscience research. Were you also there? Here we briefly summarise the exciting lectures we attended this year.

Understanding the development and progression of lineage cell types within the nervous system is critical for understanding the mechanisms of neurodegeneration and other brain diseases and can help identify potential sites for intervention. Read more and explore our primary antibodies targeting relevant markers in the neural lineage development pathways.

Chiara Musillo, a Ph.D. student from La Sapienza University of Rome, Italy, won the first Atlas Antibodies’ travel grant competition to attend the FENS Forum 2022 in Paris, held in July. Our scientists at Atlas Antibodies selected her research project among many good applications. Here is her story in her own words.

Every career path in neuroscience can be different. Written as a Guest Blog for the British Neuroscience Association BNA, we hear from Dr. Laura Pozzi, our scientific writer, an insightful and inspiring account of her daily life at Atlas Antibodies. Read about the skills and her 3 tips for you to succeed in this job. Enjoy reading!

Primary antibodies are a powerful tool in basic research. In our new research roundup dedicated to neuroscience, we talk about a mechanism responsible for drug resistance in epileptic patients and a newly discovered and evolutionarily conserved feature of oligodendrocytes.

The classification of gliomas is changing profoundly, shifting from a morphology-based guide to a system based on molecular criteria built around their genomic landscape and data from next-generation sequencing. Read more to learn about the key molecular markers that allow the latest classification of gliomas.

Check out this interview with Atlas Antibodies' Principal Scientist, Dr. Eugenia Kuteeva, to hear how our monoclonal antibodies advance discoveries in neurodegenerative diseases. The interview is published on Neuro Central, an online resource powered by Future Science Group.

Our antibodies are used in cutting-edge neuroscience research around the world. Let's take a look at three recent studies showing our antibodies in action.